In this manuscript, we present non-parametric two-sample tests for paired censored survival data incorporating longitudinal covariate information. These tests take advantage of information collected at baseline and post-baseline to provide e ciency gains when censoring is uninformative. Additionally, these methods adjust for potential bias from informative censoring that is captured by the baseline and longitudinal covariates. Finite sample properties are investigated with simulation, and we illustrate methodology with an example from the Early Treatment Diabetic Retinopathy Study.
INTRODUCTION
Most clinical trials collect prognostic baseline information in order to investigate whether treatment imbalances have occurred despite randomization and with the added hope of gaining e ciency from this prognostic information in estimation and testing of treatment e ects. In addition, it is becoming more common for clinical trials to collect longitudinal covariates as supplemental outcome information that is relevant to the primary clinical endpoint of interest. For example, the Early Treatment Diabetic Retinopathy Study [1, 2] collected eye-speciÿc baseline retinopathy status classiÿed according to two levels of prognostic disease severity and later, visual acuity scores in a study assessing early versus delayed photocoagulation for 303 Wei [14] , O'Brien and Fleming [15] , Dabrowska [16, 17] , and Jung [18] . Murray [19, 20] developed paired extensions of both sequentially monitored weighted logrank tests discussed by Gill [21] , and tests of integrated survival di erences discussed by Pepe and Fleming [22] . In her thesis, Messinger [23] developed non-parametric paired two-sample tests comparing marginal survival adjusting for baseline covariate imbalances in a causal inference manner. Although these tests accommodate paired designs, they are not able to take advantage of prognostic covariate information collected post baseline.
In this manuscript, we develop non-parametric two-sample tests for censored survival data that accommodate dependent treatment groups while incorporating longitudinal covariate information with three goals in mind. These tests extend to the paired setting (1) the ability to adjust for potential bias from informative censoring that is captured by the longitudinal covariates, (2) non-parametric baseline adjustment for treatment imbalances and, under uninformative censoring, (3) e ciency gains as additional prognostic time-dependent covariate information is incorporated without inappropriate alteration of the treatment e ect from using these potentially internal covariates. To our knowledge, no single method accomplishing these goals is available in making marginal survival comparisons in the paired censored survival setting. In Section 2, we describe baseline covariate standardized estimation of marginal survival incorporating longitudinal data. In Section 3, we present corresponding two-sample tests for paired, censored survival data. These tests use longitudinal covariate information in a manner that does not diminish treatment e ects mediated through the covariates, but instead uses the information to improve inference. We investigate ÿnite sample power and size properties of the proposed tests in Section 4. In Section 5, we revisit the ETDRS study. Discussion follows in Section 6.
SURVIVAL ESTIMATION INCORPORATING LONGITUDINAL COVARIATES AND BASELINE STANDARDIZATION
Let T g and C g denote failure and censoring random variables and X g = min(T g ; C g ) the possibly censored event time with corresponding censoring indicator g = I (T g ¡C g ); g = 1; 2. Suppose that for each of n g subjects in group g, a time-dependent categorical covariate is potentially measured at each of times T * 0 ; : : : ; T * s during the study period. When time-dependent covariates mediate treatment e ects they may be viewed as intermediate marker outcomes. For subjects in group g, let Z gm denote a time-dependent covariate observed at time T * m−1 ; m = 1; 2; 3; : : : ; s+1, with realization i m ; i m = 0; : : : ; k. Also let Â gi1 be the probability that Z g1 = i 1 at T * 0 for a subject in group g, and let Â gi1:::im be the probability that a subject in group g has Z gm = i m at T * m−1 , conditional on the subject surviving at least to time T * m−1 and previously having Z g1 = i 1 at T * 0 ; Z g2 = i 2 at T * 1 ; : : : ; and Z gm−1 = i m−1 at T * m−2 . Also, for a subject in group g, let S gi1:::im (t) be the probability that a subject survives past time t, conditional on the subject surviving past time T * m−1 and having Z 1 = i 1 at T * 0 ; Z 2 = i 2 at T * 1 ; : : : ; and Z m = i m at T * m−1 , and let H gi1:::im (t) and gi1:::im (t), respectively, denote the corresponding censoring survival and hazard functions. Using conditional probability, we may then express marginal survival for this heterogeneous distribution at times t; T * m−1 ¡t6T * m as Let n gi1:::im be the number of people in group g having Z g1 = i 1 at T * 0 ; Z g2 = i 2 at T * 1 ; : : : ; and Z gm = i m at time T * m−1 , let n gi1:::im−1 = n gi1:::im−10 + · · · + n i1:::im−1k represent the number at risk in group g at T * m−1 having previous covariate history i 1 ; : : : ; i m−1 , and letŜ gi1:::im (t) be the Kaplan-Meier survival estimate at time t among those in group g who were at risk at time T * m−1 with past covariate values corresponding to i 1 ; : : : ; i m ; m = 1; 2; : : : ; s + 1. An estimate for survival in group g at times t; T *
whereÂ gi1 = n gi1 =n g represents the group speciÿc proportion of patients in each covariate stratum as seen in each treatment group population at baseline and, for m = 1;Â gi1i2:::im = n gi1i2:::im = n gi1i2:::im−1 are group speciÿc proportions. This estimate for survival and corresponding variance results have been previously described by Murray and Tsiatis [9, 24] .
An alternative estimate for survival at times, T * m−1 ¡t6T * m , that we propose is
where n :i1 = n 1i1 +n 2i1 ; n = n 1 +n 2 , andÂ i1 = n :i1 =n represents the overall proportion of patients in covariate stratum i at baseline so it is common across treatment groups g = 1; 2. This estimate of survival adopts an approach commonly used in lifetable analysis to adjust for selection bias, where a common standardized distribution of a confounding factor is used to estimate mortality rates in each of two groups under comparison. Under successful randomization schemes, using a standardized baseline covariate distribution common to both groups in calculating WS g ; g = 1; 2, provides e ciency gains over the unstandardized estimate, WS g (t) since more data is used to estimate the common Â gi = Â i . When baseline covariate imbalances exist, use of a standardized baseline covariate distribution to estimate marginal survival in a twosample testing framework evens out baseline covariate imbalances between the groups so that di erences in marginal survival observed across groups are due only to di erences in the strata-speciÿc survival distributions themselves, and not attributable to bias caused by baseline covariate disparities. Hence, use of the unstandardized survival estimate, WS g (t) g = 1; 2, in a paired testing framework would accomplish goals (1) and (3) as stated in the Introduction, whereas use of the standardized estimate, WS g (t) g = 1; 2 would accomplish goals (1), (2) and (3). In describing WS g (t) we have assumed, without loss of generality, that T * 0 is zero so that the ÿrst set of covariates are measured at baseline. However, this estimation strategy may also accommodate settings described by Murray and Tsiatis [9, 24] in which the ÿrst covariate incorporated is measured post-baseline, and hence potentially altered by treatment, by using an artiÿcially created baseline covariate that is identical for all patients in each treatment group. By incorporating artiÿcial baseline covariates in this way, the ÿrst covariates observed at T * 1 remain unstandardized in WS g (t) and the resulting estimate corresponds to work of Murray and Tsiatis [9] where baseline imbalances could be an issue in making inferences. (t){ WS 1 (t) − WS 2 (t)} dt, where the subscript k on the test statistic matches the k subscript on the last time covariate information was collected and incorporated into the survival estimation procedure, T * k . This test statistic is powered to detect alternatives of the form
w(t)S 2 (t) dt, which is the same set of alternatives considered by the original Pepe-Fleming statistic. The random weight function,ŵ(t), must be chosen so that it vanishes whenever the number at risk within any group and stratum is zero and sup u∈[0;t) |ŵ(u) − w(u)| approaches zero in probability for deterministic w(u). For instance, if we deÿne Y gi1;:::;i k+1 (t) as the number of individuals at risk at time t for covariate history i 1 ; : : : ; i k+1 in group g;ŵ(t) = g;i1;:::;i k+1 I (Y gi1;:::;i k+1 (t)¿0) will result in an interpretation corresponding to the average years of life saved (YLS) between treatment groups during the period from (0; max(t) :ŵ(t)¿0). The limiting function w(u) associated with this choice of weight is an indicator function with positive value over the time frame where patients corresponding to each group and strata proÿle have positive probability of remaining at risk.
In calculating the asymptotic variance of this two-sample test in the paired setting, we must fully appreciate and account for correlation between survival and marker endpoints longitudinally across treatment groups. The required methodological derivation of the asymptotic test variance is included in Appendix A along with estimates for the each of its components.
Under successful randomization, it can be shown that the asymptotic variance of T PSMK is smaller than that of T PMK = (n 1 n 2 =n)
w(t){WS 1 (t) − WS 2 (t)} dt, the corresponding test we also develop in this manuscript using unstandardized WS survival estimators in place of WS, under the null hypothesis as well as under many interesting alternatives where we have uninformative censoring. For instance such alternatives includes all cases with 1 = 2 = 1=2, where g is the probability of being assigned to treatment group g. Having complete pairs is a special case where 1 = 2 . Another example is the set of alternatives where A 2i1 (0) = A 1i1 (0)+ C, where A gi1 (0) = ∞ 0 w(t)S gi1 (t) dt, and C can be interpreted as a constant, perhaps weighted, YLS due to treatment for each stratum. The null hypothesis of C = 0 is a special case of this set of alternatives. Additionally, it can be shown that e ciency gains using the standardized survival estimators are achieved under all alternatives when treatment groups are independent. Each test statistic developed for paired censored survival data in this manuscript exceeds by far the e ciency of methods currently available for independent treatment groups although we recommend use of T PSMK . A study of gains made from use of longitudinal data follows in the next section.
SIMULATIONS
Simulations relating to an 11 year study period with baseline and 4 year dichotomous marker information were constructed to investigate ÿnite sample power and size properties with independent and dependent treatment groups. Each treatment group consists of 4 possible survival proÿles constructed from piecewise bivariate lognormal failure times with a 4-year changepoint Tables I and II , where the average di erence in years lived over the ÿrst 4 years due to baseline stratum is approximately 6 months in each treatment group. Average di erences in years lived after 4 years due to covariate stratum determined at T * 1 for each treatment group depending on baseline strata 1 and 2 were approximately 2.5 and 1.5 years, respectively. Log-scale means are displayed in proximity to the curves with a 4-year change point.
as illustrated in Figure 1 . Correlation, or the lack thereof, comes from two di erent sources, the log-scale correlation parameter used in generating the piecewise bivariate lognormal curves and the degree of correlation imposed upon the longitudinal covariates. In simulations conducted with independent treatment groups, the log-scale correlation parameter, , was taken to be zero and the covariates were generated independently across treatment groups. In the correlated setting, = 0:3 and pair members shared the same covariate proÿles, unless there was induced selection bias in which case covariates were generated independently.
Parameter values corresponding to the null and alternative hypotheses, with and without selection bias, are outlined in the following paragraphs along with the results of each simulation.
Prognostic ability of the covariates in the various simulations are described using the average di erence in years lived between covariate stratum survival proÿles over a speciÿc time period. To target the degree of censoring during the 11 year study period to be 20 per cent and encourage identical study periods across all simulations, we modelled the censoring mechanism acting on the endpoints using the random variable C = L × I (B = 1) + 11 × I (B = 0). In this expression, L is a bivariate lognormal random variable with mean and variance on the log scale equal to 2.5 and correlation equal to that of the corresponding failure times, and B is a Bernoulli random variable with success probability related to the desired level of censoring. For each investigation, 1000 Monte Carlo simulations were run with 300 either uncorrelated or correlated failure time pairs.
To verify size under the null hypothesis, the log-scale means and variances of the baseline failure time distributions for each treatment group were (2:5; 1) and (1:5; 1) for covariate strata 1 and 2, respectively, corresponding to an average di erence in years lived over the ÿrst 4 years of approximately 6 months. The log-scale means and variances of the conditional failure time distributions applied to those at risk at T * 1 for each baseline covariate stratum were (2:3; 1); (0:8; 1) for covariate strata 1 and 2, respectively. These parameters a ecting survival beyond T * 1 correspond to an average di erence in years lived over the remaining study period between covariate stratum determined at T * 1 of approximately 2.5 and 1.5 years according to baseline stratum 1 and 2, respectively.
Selection bias scenarios displayed for the null hypothesis assume Â 11 = Â 22 = 0:55 and Â 12 = Â 21 = 0:45. Otherwise, in the absence of selection bias, equal proportions were designed to fall into the di erent baseline strata. Covariates generated at T * 1 were designed to fall into the di erent strata with equal proportions.
Size results are located in Table I . From top to bottom, the rows in Table I correspond to results from the paired test statistics incorporating covariate information from 2 looks (T PSM1 ), baseline only (T PSM0 ), and ignoring all covariate information (T P ). From left to right, the columns of the table represent results with independent treatment groups and then correlated treatment groups without and with selection bias. Appropriate size results were observed for paired, standardized tests using either baseline information alone or both baseline and longitudinal information in each scenario. The test statistic that ignores covariate information, T P , had in ated type I errors for the selection bias setting.
To study power, the log-scale means and variances of the four failure time distribution proÿles in each treatment group were generated to study alternatives over a range of prognostic ability of the baseline covariate. Baseline covariate prognostic ability corresponded to an average di erence in years lived between strata over the ÿrst 4 years of approximately 0; 6, or 9 months. When simulating no average di erence in years lived over the ÿrst 4 years according to baseline stratum, log-scale means and variances of the baseline failure time distributions were (2; 1) for both covariate strata 1 and 2 and treatment groups 1 and 2. For an average di erence in years lived of 6 months over the ÿrst 4 years due to baseline covariate stratum, these parameters become (2:5; 1) and (1:5; 1) for covariate strata 1 and 2, respectively. For an average di erence in years lived of 9 months over the ÿrst 4 years due to the baseline covariate stratum, these parameters become (2:8; 1) and (1:2; 1) for covariate strata 1 and 2, respectively. The log-scale means and variances of the conditional failure time distributions applied to those at risk at T * 1 depends on treatment group g, and covariate history i 1 i 2 . For those in treatment group 1, these parameters were (3:2; 1); (1:4; 1); (3:2; 1), and (1:1; 1), respectively, corresponding to covariate histories 11; 12; 21; 22. For treatment group 2, these parameters were (2:3; 1) (0:8; 1); (2:3; 1) (0:8; 1), respectively, corresponding to covariate histories 11; 12; 21; 22. These parameters a ecting survival beyond T * 1 correspond to an average di erence in years lived over the remaining study period between covariate stratum determined at T * 1 of approximately 2.5 and 1.5 years according to baseline stratum 1 and 2, respectively, in the case shown in Figure 1 . Further information on prognostic ability for the various simulation results are footnoted in the appropriate power tables.
In the absence of selection bias, equal proportions were designed to fall into the di erent baseline strata. A range of selection bias scenarios were investigated under the alternative hypotheses. Parameter values corresponding to mild selection bias were Â 11 = Â 22 = 0:55 and Â 12 = Â 21 = 0:45. These parameters become Â 11 = Â 22 = 0:60 and Â 12 = Â 21 = 0:40 for alternatives with moderate selection bias, and become Â 11 = Â 22 = 0:65 and Â 12 = Â 21 = 0:35 for an even greater degree of selection bias. Covariates generated at T * 1 were designed to fall into the di erent strata with equal proportions.
Power results located in Table II show power increasing under independent and paired settings both with and without mild selection bias with each additional incorporated covariate look. In this selection bias setting, the test statistic that ignores covariate information, T P , is too conservative while the paired standardized tests using either baseline covariate information alone or baseline and longitudinal information adjust for potential bias.
Power results located in Table III † Average di erences in years lived after 4 years between to covariate stratum determined at T * 1 for each treatment group depending on baseline strata 1 and 2 were approximately 2.5 and 1.5 years, respectively. ‡ All but one of these were rejections of the null hypothesis in favour of the inferior treatment. This is worse than having zero power since the wrong treatment is recommended in most cases.
the ÿrst 4 years of the study period. The next column indicates the test statistic for which the results are displayed in the following three columns with increasing degrees of baseline imbalance. In cases where the baseline covariate is prognostic over the ÿrst 4 years, results show power increasing with each additional incorporated covariate look as in Table  II . Comparable power results for T P and T PSM0 are displayed for all levels of selection bias when the baseline covariate is not prognostic over the ÿrst 4 years with power gains only apparent for T PSM1 in these cases. Increasing selection bias only modestly a ects the power of T PSM0 and T PSM1 as sample size increases for estimating survival curves and Â ggi2 parameters associated with Z 11 and Z 22 , and sample size decreases for estimating survival curves and Â g(3−g)i2 parameters associated with Z 12 and Z 21 . However increasing selection bias has a more profound a ect upon the power of T P , which o ers no adjustment for bias due to an imbalanced and prognostic baseline covariate. This impact of increased selection bias on T P is greater when baseline covariates have greater prognostic ability. In the worst case, illustrated in the bottom right corner of the table, the power is even worse in consequence than 0 per cent since rejections of the null hypothesis are most often in favour of the inferior treatment.
We additionally investigated power of the test statistics when the e ect of treatment manifested itself through changes in the covariate marker after baseline. Parameters to generate data were identical to those for paired data under the null hypothesis, with the exception of the parameters corresponding to the post baseline covariate distribution. In this scenario, covariates generated at T * 1 were designed to fall into covariate strata 1 and 2 with probability 0.65 and 0.35, respectively, for treatment group 1 and with probability 0.35 and 0.65, respectively, for treatment group 2 regardless of baseline status. Results are displayed in Table IV for mild selection bias or no selection bias. Again we see increased power with each additional incorporated covariate look. Although treatment di erences appear only after T • Covariates generated at T * 1 were designed to fall into covariate strata 1 and 2 with probability 0.65 and 0.35, respectively, for treatment group 1 and with probability 0.35 and 0.65, respectively, for treatment group 2 regardless of baseline status.
• Average di erences in years lived after 4 years between to covariate stratum determined at T * 1 for each treatment group depending on baseline strata 1 and 2 were approximately 2.5 and 1.5 years, respectively.
is still able to make gains in power through a coarsened capturing of the treatment e ect. In the selection bias setting presented, the test statistic that ignores covariate information, T P , is even more conservative than it was with no selection bias present.
EXAMPLE
Recall the Early Treatment Diabetic Retinopathy Study (ETDRS) described in the Introduction enrolling 3711 patients each having some degree of diabetic retinopathy in both eyes. For each patient, one eye was randomized to a treatment group receiving early photocoagulation therapy and the other to a treatment group deferring photocoagulation therapy until a time when high-risk proliferative retinopathy was detected. The clinical endpoint of interest was time to severe vision loss, where this loss was deÿned as visual acuity less than 5 200 at two consecutive visits. The statistics discussed in this paper test the di erence in average days of sight between treatment groups observed over a study period of about 8 years.
The ETDRS collected eye-speciÿc baseline retinopathy status classiÿed according to two levels of prognostic disease severity. Level of observed baseline retinopathy severity in this group is moderately predictive survival and, to a lesser degree, censoring times. For each level of baseline retinopathy, follow-up visual acuity at 3 years, deÿned as low or high visual acuity with respect to the median, is signiÿcantly predictive of survival conditional on having survived to that point as can be seen in Figure 2 . After inspection, the strata speciÿc conditional censoring survival distributions are similar amongst those at risk at 3 years. In this setting, we expect to make gains by incorporating both the baseline and 3-year prognostic covariate information.
Estimates for the average extended days of sight over the 8-year period in the early photocoagulation group along with the associated test variances are displayed in Table V . All test methods considered give similar estimates of average extended days of sight in the early photocoagulation group of about 41 days. Both tests incorporating prognostic covariate information in the paired setting perform better than the T P , the paired Pepe-Fleming test ignoring covariate information. T PSM1 , incorporating visual acuity at 3 years in addition to baseline retinopathy, leads to a 23 per cent reduction in the estimated variance of the treatment difference over T PSM0 , which uses only baseline retinopathy status.
DISCUSSION
This work develops methodology for studying paired censored survival data that makes use of baseline and internal longitudinal covariate information in a manner that improves statistical inference regarding treatment e ects. These paired tests extend the ability to adjust for potential bias from informative censoring that is captured by the longitudinal covariates, adjust for di erential selection, and can take advantage of covariate information to make e ciency gains in the absence of these sources of bias. We have demonstrated that additional e ciency gains are achieved with each prognostic covariate look under uninformative censoring in the paired censored survival setting. The potential for gaining information in the paired censored survival setting through incorporation of additional covariate information exceeds that seen when treatment groups are independent since, in the paired setting, covariate information collected longitudinally for one treatment group gives partial information about the opposing treatment group endpoint. Simulations observed in Section 4 show a tendency toward larger increases in power in the paired setting that encourage this intuition. This observation alone is a new contribution to the literature that inspires the need for more research with auxiliary covariate information in the paired censored survival setting.
When treatment groups are comparable at baseline, baseline covariate standardization advocated by this research provides e ciency gains due to additional information being used to estimate marginal survival. It should be underscored that standardization methods are only appropriate when applied to baseline covariates and not subsequent covariate information that potentially mediates treatment e ects. Standardizing post-baseline covariate distributions across treatment groups when estimating survival would potentially mask the treatment e ect of interest.
In her thesis, Messinger [23] developed stratiÿed tests for dependent treatment groups using weighted integrated survival based methods. In addition to adjusting for potential bias from baseline covariate imbalances and allowing the censoring distributions to vary by baseline stratum, incorporating baseline covariate information through stratiÿcation also yields e ciency gains when treatment alternatives are more clearly detectable within each covariate stratum. There may also be advantages to stratiÿed tests in cases where there are great disparities in the follow-up periods of the various baseline covariate strata deÿned groups, since T PSM does not take advantage of di erences beyond the end of follow-up in the least followed stratum. However, stratiÿed tests are unable to exploit the additional covariate information collected after baseline for purposes of either e ciency gain or informative censoring adjustment. Hence in cases where prognostic longitudinal information is available, T PSM gives more advantages than the paired stratiÿed tests developed by Messinger. In addition, T PSM maintains the philosophy of comparing overall marginal survival di erences in terms of years of life saved that is appealing when working with non-statistically minded investigators.
APPENDIX A
In calculating the asymptotic variance of T PSMK , the underlying correlation structure in both the survival times and longitudinal covariate information between the treatment groups must be accounted for. In what follows, we outline the strategy for calculating this asymptotic variance, with further details available from the authors upon request.
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Recall T PSM k = (n 1 n 2 =n)
where g is the overall probability of falling into treatment group g. Hence,
We ÿrst consider
To calculate this term, we use conditioning arguments with respect to F T * 1 −Z2 , representing the survival, censoring and covariate information up until and including T * 1 with the exception of the value of Z 2 . At this point, care must be taken so that WS g (t) is deÿned appropriately in each time interval. Let S gi1· (t) = P(T ¿t|T ¿T * 
After some further calculation following from equation (A1), this asymptotic closed form variance becomes (Â i1 = gi1 )
where A gi1 (x) = ∞ x w(t)S gi1 (t) dt, A hg (0) = k i1=0 Â hi1 A gi1 (0) for g; h = 1; 2 with A hg (0) = A g (0) for h = g and gi1 is the probability of falling into treatment group g for individuals in baseline strata i 1 . Also, deÿneñ i1j1 as the number of pair members in baseline stratum i 1 of group 1 with corresponding counterparts in baseline stratum j 1 of group 2, i1j1 = E(2ñ i1j1 =n), and = k i1=0 k j1=0 i1j1 . A result by Murray and Tsiatis [9] for Var √ n gi1·
gives, To derive the ÿnal term in the variance of
w(t) WS 2 (t)dt}, we again use conditioning arguments. Initially we condition only on baseline covariate information, and then calculate subsequent covariance terms by conditioning with respect to F T * 1 −Z2 . Using this strategy, we ÿrst address terms relating to covariability in the baseline covariates, and then terms relating to covariability in the corresponding survival estimates.
So, 
where Cov{n ·i1 ; n ·j1 } = Cov{n 1i1 ; n 1j1 } + Cov{n 2i1 ; n 2j1 } + Cov{n 1i1 ; n 2j1 } + Cov{n 2i1 ; n 1j1 }. This can be evaluated by recognizing that Cov{n gi1 ; n gj1 } is a multinomial covariance with sample size n g , and Cov{n 1i1 ; n 2j1 } becomes n p (Ẫ i1j1 − Â 1i1 Â 2j1 ), where n p is the total number of pairs, Â i1j1 = i1j1 = represents the proportion of pairs where the group 1 member is in baseline stratum i 1 and the group 2 member is in baseline stratum j 1 relative to the total number of pairs. Therefore, −2
Combining expressions (A3) and (A7) we have
where PF i1 = ∞ 0 w(t){S 1i1 (t) − S 2i1 (t)} dt = A 1i1 (0) − A 2i1 (0). We can also combine expressions (A2), (A8), (A9) giving us, 
We have left to evaluate Cov{ n * i1j1 ∞ 0 w(t)WS 1i1 (t) dt, n * i1j1 ∞ 0 w(t)WS 2j1 (t) dt|F * T0 }, which involves terms from correlated survival estimates after removing covariability related to baseline covariates. Before presenting the asymptotic results for this remaining covariance term, we must ÿrst deÿne some additional notation. Let T gi1;:::;im and C gi1;:::;im , respectively, denote random variables corresponding to the conditional survival and censoring survival functions S gi1:::im (t) and H gi1:::im (t) with X gi1;:::;im = min(T gi1;:::;im ; C gi1;:::;im ). Let S i1;:::;im;j1;:::;jm (u; v), H i1;:::;im;j1;:::;jm (u; v), and i1;:::;im;j1;:::;jm (u; v) represent the bivariate survival, censoring survival, and hazard functions where the group 1 pair member was at risk at time T * m−1 with covariate history corresponding to i 1 ; : : : ; i m and the group 2 pair member was at risk at time T * m−1 with covariate history corresponding to j 1 ; : : : ; j m . Also let g1i1;:::;im|g2j1;:::;jm (u|v) represent the associated conditional hazard where the pair member from group g 1 has covariate history i 1 ; : : : ; i m , and the pair member from group g 2 has covariate history j 1 ; : : : ; j m . Using this notation, deÿne G i1;:::;im;j1;:::;jm (u; v) = P(X 1i1;:::;im ¿ u; X 2j1;:::;jm ¿ v){P(X 1i1;:::;im ¿ u)P(X 2j1;:::;jm ¿v)} −1 { i1;:::;im;j1;:::;jm (u; v) − 1i1;:::;im|2j1;:::;jm (u|v) 2j1;:::;jm (v) − 2j1;:::;jm|1i1;:::;im (v|u) 1i1;:::;im (u) + 1i1;:::;im (u) 2j1;:::;jm (v)}. Let 
